search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Brain development after prenatal growth retardation; effects of growth hormone treatment.


- candidate number2390
- NTR NumberNTR865
- ISRCTNISRCTN20279720
- Date ISRCTN created26-feb-2007
- date ISRCTN requested21-feb-2007
- Date Registered NTR5-jan-2007
- Secondary IDsN/A 
- Public TitleBrain development after prenatal growth retardation; effects of growth hormone treatment.
- Scientific TitleBrain development after prenatal growth retardation; effects of growth hormone treatment.
- ACRONYMsga brain development study
- hypothesisThis study aims to evaluate the effect of growth hormone treatment on brain functioning and development in children born with a low birth weight/length with incomplete catch up growth. The two other hypotheses this study aims to evaluate are a. Is there a difference in brain functioning in children born with a low birth weight/length between those without and with complete catch up growth? b.Will intra-uterine growth failure affect brain development/functioning?
- Healt Condition(s) or Problem(s) studiedSmall for gestational age (SGA), Brain development
- Inclusion criteriaInclusion criteria group A/B: 1.Birth weight or birth length below –2 SD adjusted for duration of pregnancy; 2. Present height below –2.5 SD and at least 1 SD below target height-SDS; 3. Calendar age between 4 and 6 years. 4. No evidence of catch up growth during the preceding year; 5. Children are under regular control by pediatrician, choose to be or not to be treated with GH. Inclusion criteria group C: 1. Birth weight or birth length below –2 SD adjusted for duration of pregnancy; 2. Present height above -2.0 SD and above minus 1 SD of target height -SDS. Inclusion criteria group D: 1. Normal birth weight/length adjusted for duration of pregnancy; 2. Present height above –2 SD for age and within target range (TH ± 1SD ).
- Exclusion criteria1. Known syndromes and serious dysmorphic symptoms suggestive for a syndrome that has not yet been described, except for Silver Russell Syndrome; 2. Severe asphyxia (defined as Apgar score <3 after 5 minutes), and no serious diseases such as long-term artificial ventilation and oxygen supply, bronchopulmonary dysplasia or other chronic lung disease; 3. Coeliac disease and other chronic or serious diseases of the gastrointestinal tract, heart, genito-urinary tract, liver, lungs, skeleton or central nervous system, or chronic or recurrent major infectious diseases, nutritional and/or vitamin deficiencies; 4. Any endocrine or metabolic disorder such as diabetes mellitus, diabetes insipidus, hypothyroidism, or inborn errors of metabolism, except of GHD; 5. Medications or interventions during the previous 6 months that might have interfered with growth, such as corticosteroids (including high dose of corticosteroid inhalation), sex steroids, growth hormone, or major surgery (particularly of the spine or extremities); 6. Use of medication that might interfere with growth during GH therapy, such as corticosteroids, sex steroids, LHRH analogue; 7. Active or treated malignancy or increased risk of leukemia; 8. Serious suspicion of psychosocial dwarfism (emotional deprivation); 9. Severe neurological disability; 10. Expected non-compliance; 11. Prematurity < 35 weeks; 12. For MEG/MRI investigation: Treatment with irremovable metal wires.
- mec approval receivedno
- multicenter trialno
- randomisedno
- groupParallel
- Type-
- Studytypeintervention
- planned startdate 1-mrt-2007
- planned closingdate1-mrt-2011
- Target number of participants110
- InterventionsStructural (only at baseline) and functional MRI’s, MEG and extensive neuropsychologic testing will be performed at baseline, after one year and three years in both groups A (treatment with growth hormone (somatropin) and B (without treatment). SGA patients older than 6 years of age, with incomplete catch-up growth with the indication of GH treatment, will be followed on neuropsychologic functioning. hypothesis 2/ 3: In groups C and D structural and functional MRI’s, MEG and extensive neuropsychological testing will be performed only at start of the study.
- Primary outcome1. To determine the effect of prenatal growth retardation on brain functioning / development; 2. to determine the effect of growth hormone treatment on brain functioning / development in children born after prenatal growth retardation; 3. to assess wether there is a difference in brain development in between sga children with and without postnatal catch up growth.
- Secondary outcomeN/A
- Timepoints
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIES H.M.A. Bie, de
- CONTACT for SCIENTIFIC QUERIES H.M.A. Bie, de
- Sponsor/Initiator Pfizer BV
- Funding
(Source(s) of Monetary or Material Support)
VU University Medical Center, Department of Pediatric Endocrinology
- PublicationsN/A
- Brief summaryThis study aims to evaluate the effect of growth hormone treatment on brainfunctioning/ development in children born after prenatal growth retardation. Whether cognitive functions in children born with a low birth weight are impaired due to inappropriate developmental outgrowth is unknown. This is also the case for the fact whether GH treatment from the age of 4 years is still capable to stimulate neuronal outgrowth. We expect the presented study design in which functional imaging techniques and neuropsychological assessment are combined, to increase understanding on the impact of GH therapy on higher brain functioning in children with SGA.
- Main changes (audit trail)
- RECORD5-jan-2007 - 26-feb-2007


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl